Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

Semaglutide vs Tirzepatide (Ozempic vs Mounjaro): Deep Comparison

Back to library
peptide

Semaglutide vs Tirzepatide (Ozempic vs Mounjaro): Deep Comparison

17 min read
Compound Guide
GLP-1 Research
Research Comparison
Metabolic Research
Last Updated: May 2026

Prescription-Only Medicine — Important Notice

Both semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are prescription-only medicines in the UK and most jurisdictions. For research purposes only. Not for human consumption. Pure Grade Labs cannot provide prescribing advice and does not supply these compounds for therapeutic use.

Semaglutide vs tirzepatide — or Ozempic vs Mounjaro in their branded clinical forms — is the defining comparison question in GLP-1 receptor pharmacology research: does adding GIP receptor agonism to GLP-1 receptor agonism produce meaningfully superior outcomes, and what does that tell us about the mechanistic contribution of each receptor pathway? Semaglutide is a selective GLP-1 receptor monoagonist — it targets one receptor, providing researchers with a pharmacologically clean GLP-1R signal. Tirzepatide is a dual GIP+GLP-1 receptor agonist — a single peptide with activity at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GLP-1 receptor (GLP-1R), producing a combined signal whose mechanistic dissection is one of the most active areas of incretin pharmacology research.

Head-to-head clinical trial data (SURPASS-2, Frias JP et al. 2021, NEJM) shows tirzepatide achieving superior HbA1c reduction and greater body weight outcomes compared to semaglutide 1mg in T2D. SURMOUNT-1 (Jastreboff AM et al. 2022, NEJM) showed tirzepatide 15mg producing a mean 20.9% body weight reduction over 72 weeks — outcomes that, in research terms, raised fundamental questions about the additive versus synergistic contribution of the GIP receptor to incretin-mediated metabolic effects. This article presents the mechanistic, pharmacological, and clinical trial data behind the semaglutide vs tirzepatide comparison — framed for researchers studying GLP-1 axis pharmacology. Both compounds are prescription-only medicines (POM) in the UK. For research purposes only. Not for human consumption.

Key Takeaways

  • Semaglutide (CAS: 910463-68-2; MW: 4,113.6 Da) is a GLP-1 receptor monoagonist with 94% homology to native GLP-1 and ~7-day half-life via C18 fatty acid modification — the pharmacological standard for isolating GLP-1R signalling in research.
  • Tirzepatide (CAS: 2023788-19-2; MW: 4,813.5 Da) is a dual GIPR+GLP-1R agonist — a single 39-amino acid peptide engineered to activate both incretin receptors simultaneously, enabling research into the combined GIP+GLP-1 pathway contribution.
  • SURPASS-2 head-to-head trial: tirzepatide 15mg produced superior HbA1c reduction (−2.46% vs −2.07% for semaglutide 1mg) and greater weight reduction (−5.5kg vs −4.7kg) at 40 weeks (Frias JP et al. 2021, NEJM).
  • SURMOUNT-1 trial: tirzepatide 15mg over 72 weeks — mean 20.9% body weight reduction vs 3.1% placebo; 63% of participants achieved ≥20% body weight loss (Jastreboff AM et al. 2022, NEJM).
  • The mechanistic research question: is tirzepatide’s superior efficacy due to additive GIP+GLP-1 signalling, synergistic receptor cross-talk, or GIP-mediated attenuation of GLP-1-induced GI effects? Both compounds are needed to answer this — semaglutide establishes the GLP-1R-only baseline; tirzepatide adds the GIP dimension.
14.9%
Mean body weight reduction with semaglutide 2.4mg over 68 weeks vs 2.4% placebo — STEP-1 trial, Wilding JPH et al. 2021, NEJM (n=1,961)
20.9%
Mean body weight reduction with tirzepatide 15mg over 72 weeks vs 3.1% placebo — SURMOUNT-1 trial, Jastreboff AM et al. 2022, NEJM
63%
Proportion of SURMOUNT-1 participants on tirzepatide 15mg who achieved ≥20% body weight loss — a threshold rarely observed with prior pharmacological approaches
~7 days
Plasma half-life for both semaglutide and tirzepatide — both support once-weekly administration in clinical trial protocols

Source Semaglutide and Tirzepatide for Research

HPLC-verified purity. Batch-specific COA. Both compounds available as research-grade materials. Prescription-only medicine. Not for human consumption.

View GLP-1 Research Compounds →

The Fundamental Mechanistic Distinction: Monoagonist vs Dual Agonist

To understand the semaglutide vs tirzepatide comparison, the starting point is receptor pharmacology — specifically, the incretin system. Incretins are gut-derived hormones released in response to nutrient ingestion that amplify glucose-stimulated insulin secretion from pancreatic beta cells. The two primary incretin hormones in human physiology are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both act via specific G-protein coupled receptors: GLP-1R and GIPR respectively, expressed in pancreatic beta cells, alpha cells, and a range of extra-pancreatic tissues including brain, gut, bone, and adipose tissue.

The historical approach to incretin pharmacology was to target GLP-1R selectively — on the basis that GLP-1 had the stronger established insulinotropic and appetite-suppressing profile, and that GIP was considered less tractable (early research showed that in the T2D state, the insulinotropic effect of GIP was blunted, leading to GIP being termed the “forgotten incretin”). Semaglutide is the pinnacle of this GLP-1R-selective approach.

Tirzepatide represents a paradigm shift: the hypothesis that GIP receptor agonism, rather than being unhelpful or redundant, might actually enhance the metabolic effects of GLP-1R activation — either additively, synergistically, or by attenuating GLP-1R-induced side effects via GIPR-mediated mechanisms. The SURPASS and SURMOUNT trial data strongly support this hypothesis, but the mechanistic basis remains an active area of research.

Semaglutide (Ozempic/Wegovy): Pharmacological Profile

Semaglutide (CAS: 910463-68-2; MW: 4,113.6 Da) is a 31-amino acid GLP-1 analogue with 94% structural homology to native human GLP-1(7-36)amide. Two key structural modifications distinguish it from native GLP-1 and from earlier GLP-1 analogues (such as liraglutide): a C18 fatty di-acid moiety attached via a linker to lysine at position 34, which enables strong reversible albumin binding; and an Aib (α-aminoisobutyric acid) substitution at position 8, which confers resistance to DPP-IV proteolytic cleavage. Together, these modifications produce a plasma half-life of approximately 7 days, enabling once-weekly subcutaneous administration in trial protocols — compared to once-daily for liraglutide.

Semaglutide acts exclusively at the GLP-1 receptor. Its mechanism of action at GLP-1R involves: glucose-dependent stimulation of insulin secretion from pancreatic beta cells; suppression of inappropriately elevated glucagon from alpha cells; delayed gastric emptying; and central nervous system effects on appetite and energy intake via GLP-1R in the hypothalamus and brainstem. The weight-reduction effects of semaglutide observed in clinical trials are primarily attributed to CNS appetite suppression and energy intake reduction — not solely peripheral glucose metabolism.

STEP-1 and SUSTAIN Trial Data

The primary phase III data for semaglutide spans two programmes:

  • SUSTAIN programme (T2D): The primary SUSTAIN trials examined doses of 0.5mg and 1.0mg weekly for type 2 diabetes management. SUSTAIN-6 (Marso SP et al. 2016, NEJM) demonstrated a significant reduction in MACE (major adverse cardiovascular events) with semaglutide vs placebo — a cardiovascular outcomes result that validated GLP-1R agonism beyond glycaemic control.
  • STEP-1 (obesity): Wilding JPH et al. (2021, NEJM) — semaglutide 2.4mg weekly over 68 weeks in 1,961 adults with overweight/obesity without T2D. Mean body weight reduction: 14.9% from baseline vs 2.4% placebo (p<0.001). 86.4% of semaglutide participants achieved ≥5% weight loss vs 31.5% placebo. This established semaglutide 2.4mg as a pharmacological benchmark for GLP-1R agonist-mediated weight reduction.

Tirzepatide (Mounjaro/Zepbound): Pharmacological Profile

Tirzepatide (CAS: 2023788-19-2; MW: 4,813.5 Da) is a 39-amino acid synthetic peptide developed by Eli Lilly and Co., engineered as a single molecule with dual agonist activity at both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). It is based on the native GIP sequence, modified with a C18 fatty di-acid moiety (similar to the albumin-binding strategy in semaglutide) and structural modifications at key positions to confer GLP-1R binding activity alongside GIPR agonism. Half-life is approximately 5–7 days, supporting once-weekly dosing in trial protocols.

The term “twincretin” (coined in the pharmacological literature to describe tirzepatide’s dual mechanism) reflects the conceptual novelty: both incretin hormone receptor systems are activated by a single exogenous ligand. At GIPR, tirzepatide stimulates insulin secretion, inhibits glucagon, and acts on adipose tissue and CNS via GIPR-expressing cells. At GLP-1R, it recapitulates the established semaglutide mechanism — glucose-dependent insulin release, glucagon suppression, gastric emptying delay, and appetite-suppressant CNS signalling. The combined activation profile produces metabolic effects that exceed what semaglutide (GLP-1R monoagonist) achieves at comparable doses.

Critically for mechanistic research, tirzepatide’s relative potency at GIPR vs GLP-1R is not equivalent: its GIP receptor activity is approximately 5-fold higher than its GLP-1R activity (based on receptor binding assay data), meaning the GIPR contribution is pharmacologically dominant in the dual signal. Understanding what this asymmetry means for metabolic outcomes — and whether GIP receptor agonism enhances, attenuates, or modulates the GLP-1R response — is one of the central mechanistic questions in current incretin pharmacology research.

SURPASS and SURMOUNT Trial Data

The phase III data for tirzepatide spans two large programmes:

  • SURPASS programme (T2D): Examined doses of 5mg, 10mg, and 15mg weekly across multiple T2D populations. SURPASS-2 (Frias JP et al. 2021, NEJM) was the pivotal head-to-head comparison against semaglutide 1mg — see comparison section below.
  • SURMOUNT-1 (obesity): Jastreboff AM et al. (2022, NEJM) — tirzepatide at 5mg, 10mg, and 15mg weekly over 72 weeks in adults with BMI ≥30 or ≥27 with weight-related complication. At 15mg: mean body weight reduction 20.9% vs 3.1% placebo. At 10mg: 19.5% reduction. At 5mg: 15.0% reduction. 63% of 15mg participants achieved ≥20% body weight loss — a proportion that had not been achieved with any prior pharmacological approach in controlled trial conditions. These results redefined the ceiling of pharmacologically achievable weight reduction.

Semaglutide vs Tirzepatide Head-to-Head: SURPASS-2 Data

The SURPASS-2 trial (Frias JP et al. 2021, NEJM) is the only published head-to-head randomised controlled trial directly comparing tirzepatide and semaglutide. It enrolled 1,879 adults with T2D (on background metformin) and compared tirzepatide (5mg, 10mg, 15mg weekly) vs semaglutide 1mg weekly over 40 weeks. Key findings at 40 weeks:

Parameter (40 weeks) Semaglutide 1mg Tirzepatide 5mg Tirzepatide 10mg Tirzepatide 15mg
HbA1c reduction (% points) −2.07% −2.09% −2.37% −2.46%
Body weight reduction (kg) −4.7kg −6.2kg −8.0kg −5.5kg*
Achieved HbA1c <7% 68% — — 82%
Nausea (any grade) ~18% ~17% ~19% ~22%
Study design SURPASS-2 (Frias JP et al. 2021, NEJM). n=1,879 T2D adults on metformin background. Randomised, open-label, active-controlled. *Weight reduction for tirzepatide 15mg reported at 40 weeks; −5.5kg cited vs semaglutide −4.7kg. Higher tirzepatide doses achieved greater weight reductions in dose-dependent manner.

SURPASS-2 data: Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503–515. The trial used semaglutide 1mg (not 2.4mg obesity dose). Comparison against the higher 2.4mg semaglutide dose (as used in STEP-1) would require separate analysis — no direct RCT has been published comparing tirzepatide head-to-head vs semaglutide 2.4mg as of May 2026.

The Central Mechanistic Research Question: What Is GIP Receptor Agonism Actually Doing?

The SURPASS and SURMOUNT data raise a question that cannot be answered by clinical trial efficacy data alone: what is the mechanistic contribution of GIP receptor agonism to tirzepatide’s superior outcomes compared to GLP-1R agonism alone? This is the question driving current comparative mechanistic research using semaglutide (GLP-1R monoagonist) and tirzepatide (GIP+GLP-1R dual agonist) as paired pharmacological tools.

Several mechanistic hypotheses are currently under investigation in preclinical and clinical research:

Hypothesis 1: Additive Incretin Signalling

The simplest hypothesis: GIP receptor agonism adds a second insulinotropic and anabolic signal to the GLP-1R-mediated effects, and the sum of both signals exceeds what GLP-1R alone produces. Both GIPR and GLP-1R are expressed on pancreatic beta cells and signal through Gsα → adenylyl cyclase → cAMP → PKA pathways — potentially producing additive intracellular cAMP elevation and thus greater insulin secretory and cellular metabolic responses. This hypothesis would predict a dose-dependent advantage for tirzepatide over semaglutide, which is broadly consistent with the SURPASS-2 dose-response data.

Hypothesis 2: GIP-Mediated GLP-1R Upregulation or Sensitisation

An alternative hypothesis: GIPR activation may upregulate or sensitise GLP-1R expression or signalling downstream, effectively amplifying the GLP-1R component of tirzepatide’s activity beyond what semaglutide achieves at equivalent GLP-1R occupancy. Some preclinical data suggest GIPR signalling can modulate GLP-1R expression in beta cells, though the magnitude and clinical relevance of this effect remains under investigation. If confirmed, this would represent a synergistic (rather than merely additive) relationship between the two receptor pathways.

Hypothesis 3: GIP Receptor Agonism Attenuates GLP-1R-Induced GI Side Effects

A particularly important hypothesis from a research design perspective: GIP receptor agonism in the GI tract may attenuate the nausea and vomiting that are the primary dose-limiting side effects of GLP-1R agonists. GLP-1R-mediated GI effects are largely driven by peripheral vagal afferent activation and central area postrema (AP) signalling. GIPR is expressed in GI tissues, and GIPR activation may counteract or modulate the GLP-1R-mediated gastric emptying delay and nausea signalling. This would explain why tirzepatide — despite producing greater metabolic outcomes — shows a nausea profile that is not proportionally worse than semaglutide in trial data. This hypothesis is directly testable using comparative research designs with semaglutide and tirzepatide in GI motility and vagal signalling models.

Hypothesis 4: Adipose Tissue GIPR Action as a Direct Metabolic Mechanism

GIP receptor is expressed on adipocytes, and GIPR activation in white adipose tissue is proposed to affect lipid storage, fatty acid mobilisation, and adipokine secretion — potentially contributing directly to tirzepatide’s superior weight reduction outcomes through a mechanism that has no equivalent in semaglutide’s GLP-1R-only pharmacology. Some research has suggested that adipose GIPR activation may facilitate fatty acid utilisation and reduce lipid accumulation in visceral fat depots, but the functional direction of GIPR effects on adipose tissue (pro-lipogenic vs lipolytic) is context-dependent and remains an active research question.

Research-Grade Semaglutide and Tirzepatide

Supply both compounds for mechanistic GLP-1 pharmacology research. HPLC-verified. Batch-specific COA. POM — for research purposes only. Not for human consumption.

Semaglutide = GLP-1R monoagonist reference. Tirzepatide = GIP+GLP-1R dual agonist experimental.

Research Applications: Why Both Compounds Are Used in Comparative GLP-1 Research

The value of having both semaglutide and tirzepatide as research tools is precisely their mechanistic contrast. Semaglutide provides a pharmacologically clean GLP-1R-only signal — a monoagonist reference compound against which the incremental contribution of GIPR activation can be measured. Tirzepatide adds the GIP dimension. Running parallel in vitro or in vivo protocols with both compounds — at dose-matched or receptor-matched conditions — allows researchers to attribute differential outcomes specifically to the GIP receptor contribution.

Specific research applications enabled by this comparative approach include:

  • Beta cell function research: Comparing insulin secretion amplification, beta cell cAMP kinetics, and beta cell viability/proliferation between GLP-1R-only and GLP-1R+GIPR activation — identifying whether the GIP component confers beta cell preservation benefit independently of glycaemic effects.
  • Adipose tissue metabolism: Using in vitro adipocyte models or ex vivo fat tissue to directly compare the lipolytic, lipogenic, and adipokine secretion profiles of semaglutide vs tirzepatide — isolating the GIPR contribution to adipose tissue remodelling.
  • CNS appetite circuitry: Comparing hypothalamic and brainstem neuronal activation (POMC, AgRP, NPY circuits) between GLP-1R-only and GIP+GLP-1R activation in rodent models — assessing whether GIPR activation in the CNS contributes independently to appetite suppression and energy intake reduction.
  • GI motility and tolerability research: Examining gastric emptying delay, nausea-related signalling (area postrema, vagal afferents), and GI motility parameters — comparing the GI pharmacodynamic profile of semaglutide vs tirzepatide to investigate whether GIPR modulates GLP-1R-induced GI effects.
  • Metabolic syndrome models: Using diet-induced obesity or genetically obese rodent models to compare the full metabolic phenotype (body composition, glucose tolerance, lipid profile, hepatic steatosis) between semaglutide and tirzepatide research protocols — quantifying the additive value of dual receptor engagement.

Pure Grade Labs also supplies Retatrutide 10mg — a triple agonist at GIP receptor, GLP-1 receptor, and glucagon receptor (GcgR). Retatrutide represents the next mechanistic step beyond tirzepatide: the addition of glucagon receptor agonism to the GIP+GLP-1 dual agonist scaffold. Phase II data (Jastreboff AM et al. 2023, NEJM) showed mean body weight reduction of 24.2% at 48 weeks with retatrutide 12mg — establishing a dose-response pattern across the GLP-1R monoagonist → GIP+GLP-1R dual agonist → GIP+GLP-1+GcgR triple agonist progression that is one of the most compelling mechanistic narratives in current metabolic research. The Metabolic Research Combination and Appetite and Fat Loss Research Combination from Pure Grade Labs provide matched supply of these complementary compounds.

A research group investigating the mechanistic basis of GLP-1-based pharmacology runs parallel protocols in a diet-induced obesity (DIO) mouse model: one arm receiving semaglutide at GLP-1R-occupancy-matched doses, the second arm receiving tirzepatide at matched GLP-1R activity with additional GIPR engagement. The differential outcomes — in body weight, adipose depot composition, hepatic lipid content, and plasma adipokine profile — between the two arms directly quantify the GIPR contribution. Neither semaglutide nor tirzepatide alone can answer the research question; the comparison is the experiment.

Frequently Asked Questions — Semaglutide vs Tirzepatide (Ozempic vs Mounjaro)

What is the key mechanistic difference between semaglutide and tirzepatide?

Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor monoagonist — it activates only the GLP-1 receptor and provides a pharmacologically clean GLP-1R signal. Tirzepatide (Mounjaro/Zepbound) is a dual agonist — a single peptide that simultaneously activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). This “twincretin” mechanism is the central distinction and the basis for tirzepatide’s superior outcomes in head-to-head trial data.

Which performed better in head-to-head trial data — Ozempic or Mounjaro?

SURPASS-2 (Frias JP et al. 2021, NEJM) compared tirzepatide (5mg, 10mg, 15mg) vs semaglutide 1mg in T2D over 40 weeks. Tirzepatide 15mg produced superior HbA1c reduction (−2.46% vs −2.07%) and greater body weight reduction vs semaglutide 1mg. The SURMOUNT-1 data for tirzepatide showed 20.9% mean weight reduction at 72 weeks, compared to 14.9% for semaglutide 2.4mg in the separate STEP-1 trial. Note these were separate trials with different populations and dose comparisons — the only direct RCT published is SURPASS-2 vs semaglutide 1mg. Research purposes only. Not medical advice.

What are the molecular weights and CAS numbers of semaglutide and tirzepatide?

Semaglutide: CAS 910463-68-2, MW 4,113.6 Da, 31 amino acids. Tirzepatide: CAS 2023788-19-2, MW 4,813.5 Da, 39 amino acids. Both have approximately 7-day plasma half-lives supporting once-weekly administration in trial protocols.

Are semaglutide and tirzepatide available as research chemicals in the UK?

Both semaglutide and tirzepatide are prescription-only medicines (POM) in the UK under the Human Medicines Regulations 2012. They are also available as research-grade materials for laboratory research under appropriate research purchasing terms. Pure Grade Labs supplies both as HPLC-verified research compounds — not for human consumption or therapeutic use.

What comes after tirzepatide in the incretin pharmacology research progression?

Retatrutide — a triple agonist at GIP receptor, GLP-1 receptor, and glucagon receptor (GcgR) — is the next compound in the mechanistic progression. Phase II trial data (Jastreboff AM et al. 2023, NEJM) showed mean body weight reduction of 24.2% at 48 weeks with retatrutide 12mg. The GLP-1R → GIP+GLP-1R → GIP+GLP-1+GcgR progression provides a mechanistic framework for understanding the incremental contribution of each receptor pathway to metabolic outcomes.

Why does tirzepatide show similar nausea rates to semaglutide despite greater efficacy?

This is one of the active mechanistic research questions in incretin pharmacology. One hypothesis is that GIP receptor agonism in GI tissue modulates or attenuates the GLP-1R-mediated gastric emptying delay and vagal nausea signalling that drives GLP-1R agonist-induced nausea. If GIPR activation counteracts the GI tolerability liabilities of GLP-1R agonism while preserving or enhancing its metabolic benefits, this would represent a mechanistically important property of dual GIP+GLP-1R agonism. Published SURPASS-2 nausea data shows comparable rates between tirzepatide doses and semaglutide 1mg — but the mechanistic explanation requires preclinical investigation using both semaglutide and tirzepatide in controlled research models.

Complete GLP-1 Research Compound Supply

Semaglutide, Tirzepatide, and Retatrutide — the monoagonist, dual agonist, and triple agonist progression. HPLC-verified. Research use only.

POM compounds. Not for human consumption. For laboratory research purposes only.

Summary

The semaglutide vs tirzepatide comparison — Ozempic vs Mounjaro in their clinical forms — is fundamentally a question about receptor pharmacology: what does adding GIP receptor agonism to GLP-1 receptor agonism accomplish, and through what mechanism? Semaglutide (CAS: 910463-68-2) provides the GLP-1R-only baseline; tirzepatide (CAS: 2023788-19-2) adds the GIP dimension. Published head-to-head data (SURPASS-2) establishes tirzepatide’s clinical superiority at matched dosing; SURMOUNT-1 showed 20.9% body weight reduction at 15mg — outcomes that have redefined expectations in metabolic pharmacology research.

The mechanistic question — whether GIP’s contribution is additive, synergistic, or operates via GI tolerability modulation and direct adipose tissue action — cannot be resolved by clinical efficacy data alone. Comparative preclinical and mechanistic research using both compounds as paired pharmacological tools is the approach that will answer it. Pure Grade Labs supplies both as HPLC-verified research compounds, alongside Retatrutide as the next step in the agonist progression, and matched Metabolic and Appetite and Fat Loss Research Combinations for researchers requiring paired supply.

Both compounds are prescription-only medicines (POM) in the UK. Pure Grade Labs supplies them strictly for laboratory research under HMR 2012 — not for human consumption, therapeutic use, or personal administration.

References

  1. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519 (SURPASS-2)
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038 (SURMOUNT-1)
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 (STEP-1)
  4. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141 (SUSTAIN-6)
  5. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972 (Retatrutide Phase II)
  6. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009 (Tirzepatide discovery and mechanism)
  7. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–536. doi:10.1016/S2213-8587(15)00482-9 (Incretin biology review)
  8. Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006 (GIP+GLP-1 mechanistic review)

Disclaimer: This article is published for informational and scientific research purposes only. Semaglutide and tirzepatide are prescription-only medicines (POM) in the UK under the Human Medicines Regulations 2012 (HMR 2012). Pure Grade Labs supplies these compounds strictly as research-grade materials for laboratory research use — not for human consumption, therapeutic use, self-administration, or weight management. Nothing in this article constitutes medical advice, prescribing guidance, or a recommendation for personal use. Clinical trial data cited herein is drawn from published peer-reviewed literature and is presented for scientific accuracy. Individuals seeking medical guidance on any medicine or therapeutic intervention should consult a licensed medical professional. Pure Grade Labs cannot provide prescribing advice and does not operate as a clinical service. For research purposes only.